Table 1.

Characteristics of studies included in the review.

	Medication	Disease	Study design	Timing of exposure	Number of patients exposed	Live births	Major birth defects	Low birth weight	Preterm births	Stillbirths
1	Omalizumab	Asthma	The Observational Study of the Use and Safety of Xolair (omalizumab) During Pregnancy (EXPECT) (Namazy, Blais et al. 2020) [8, 9]	246 patients were exposed during first trimester	230	233 (99.1%) (223 singletons and 10 twins)	(8.1%)	(13.7%)	(15%)	2 (0.9%)
2		Asthma	Retrospective case study (Gemicioğlu, Yalçin et al. 2021) [12]	Variable	20	23 (2 twins)	0	3	5	0
3		Asthma	Case reports (Kupryś-Lipińska, Tworek et al. 2014) [13]	Throughout pregnancy	2	2	0	0	0	0
4		Asthma	Case report (Hirashima, Hojo et al. 2012) [14]	First trimester	1	1	0	1	1	0
5		Asthma	Case report (Kuschnir, Emerson et al. 2012) [15]	First trimester	1	1	0	0	0	0
6		Asthma	Case report (Cortese, Di Lizia et al. 2013) [16]	First trimester	1	1	0	NA	1	0
7		Asthma	Case report (Majou, Moreira et al. 2021) [17]	Throughout pregnancy	1	1	0	0	0	0
8		CIU	Observational study (EXPECT) (Namazy, J., 2021) [18]	First trimester	30	29	2	1	4	0
9		CIU	Case report (Cuervo-Pardo, Barcena-Blanch et al. 2016) [19]	Throughout pregnancy	4	4	0	0	0	0
10		CIU	Case report (Liao, Yu et al. 2021) [20]	Variable	2	2	0	0	0	0
11		CIU	Case report (Losappio, Mirone et al. 2020) [21]	Throughout pregnancy	1	1	0	0	0	0
12		CIU	Case report (Ensina, Cusato-Ensina et al. 2017) [22]	Variable	2	3 (2 twins)	0	0	0	0
13		CIU	Case report (Ghazanfar and Thomsen 2015) [23]	Throughout pregnancy	1	2 (conceived twice)	0	0	0	0
14		CIU	Case report (Gonzalez-Medina, Curto-Barredo et al. 2017) [24]	Variable	2	2	0	0	0	0
15	Mepolizumab	Asthma	Case report (Ozden and Pinar Deniz 2021) [28]	First trimester	2	1	0	0	0	0
16		Severe eosinophilic granulomatosis with polyangiitis	Case report (Kasuya, Kitano et al. 2019) *	Exposed after delivery	1	N/A (Due to time of exposure)	N/A	N/A	N/A	N/A
17	Benralizumab	Hypereosinop hilic syndrome with severe eosinophilic gastrointestin al involvement	Case report (Manetz, Marie et al. 2021) [32]	Throughout pregnancy	1	1	0 (0 eosinophil count at birth to 7 months)	0	0	0
18		Asthma	Case report (Saco and Tabatabaian 2018) [33] **	Third trimester	N/A	N/A	N/A	N/A	N/A	N/A
19	Dupilumab	Atopic dermatitis	Case series (Bosma, Gerbens et al. 2021) [48]	2 men at conception 2 women prior to conception	4	4	0	0	0	0
20		Atopic dermatitis	Case report (Lobo, Lee et al. 2021) [40]	First and second trimester	1	1	0	0	0	0
21		Atopic dermatitis	Case report (Kage, Simon et al. 2020, Kage, Simon et al. 2021) [41, 42]	Throughout pregnancy	1	1	0	0	0	0
22		Atopic dermatitis	Case report (Mian, Dunlap et al. 2020) [43]	Third trimester	1	1	0	0	0	0
23		Atopic dermatitis	Case report (Gracia-Darder, Pons De Ves et al. 2021) [44]	Throughout pregnancy	1	1	0	0	0	0
24		Atopic dermatitis	Case report (Costley and Murphy 2021) [45]	Throughout pregnancy	1	1	0	0	0	0
25		Atopic dermatitis	Case report (Akhtar, Khosravi-Hafshejani et al. 2022) [47]	Throughout pregnancy	1	1	0	1	0	0
26		Pemphigoid gestationis	Case report (Riquelme-McLoughlin and Mascaró 2021) [46]	Third trimester	1	1	0	N/A	1	0
Total					313	318	21	38	47	2

N/A = Not available/Not applicable

CIU = Chronic idiopathic urticaria

^*Mepolizumab was given after the delivery. Therefore, pregnancy outcomes could not be attributed to mepolizumab use.

^**Exposed to benralizumab during pregnancy. However, no further information on fetal outcomes was provided.